Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events - REPLACE 2 Long-Term Follow-up


The goal of the REPLACE 2 long-term follow-up study was to determine if there was a clinical benefit at six-month follow-up between the use of bivalirudin and unfractionated heparin (UFH) with planned glycoprotein (GP) IIb/IIIa inhibitor use during elective or urgent percutaneous coronary intervention (PCI).